Recruiting
Plasma cell myeloma
RecruitingStudy on the Safety and Effectiveness of Teclistamab and Talquetamab for Patients with Newly Diagnosed Multiple Myeloma Eligible for Transplant
Registered drugNo placebo
Study on the Safety and Effectiveness of Teclistamab and Talquetamab for Patients with Newly Diagnosed Multiple Myeloma Eligible for Transplant
Registered drugNo placebo
- Disease:Plasma cell myeloma
- Substances:BortezomibDaratumumab+5
Countries:
Germany
Germany- Participants:18–64 years · 65+ years
- Substances:Bortezomib
